Spark Therapeutics announced the appointment of Federico Mingozzi, as chief scientific officer. He will report to Katherine A. High, M.D., who will continue as the company’s president and head of R&D. Dr. High will also continue to serve on the board of directors. Dr. Mingozzi joins Spark Therapeutics from the French National Institute of Health and Medical Research (INSERM) and Genethon. He serves as faculty at the Pierre and Marie Curie University in Paris and Universitat Autonoma de Barcelona, Spain. Dr. Mingozzi has had a distinguished career in gene therapy research, including earlier as director of translational research, Center for Cellular and Molecular Therapeutics, at Children’s Hospital of Philadelphia, where he was involved in the development of gene therapies based on the AAV vector platform.